| Date | Source | Headline | |
|---|---|---|---|
| 8th Oct 2014 | 4:03 pm | RNS | US Regulatory Approval |
| 2nd Oct 2014 | 7:18 am | RNS | Ameluz Phase III Preliminary Results |
| 8th Sep 2014 | 6:21 pm | RNS | Director/PDMR Shareholding |
| 4th Sep 2014 | 1:50 pm | RNS | Director/PDMR Shareholding |
| 4th Sep 2014 | 7:00 am | RNS | Director/PDMR Shareholding |
| 4th Sep 2014 | 7:00 am | RNS | Update Re: Biosynth AG |
| 29th Aug 2014 | 7:00 am | RNS | Half Yearly Report |
| 22nd Aug 2014 | 7:00 am | RNS | Notice of Results |
| 21st Aug 2014 | 1:30 pm | RNS | FDA pre-New Drug Application meeting for Ameluz |
| 21st Aug 2014 | 7:00 am | RNS | Filing Re: Biosynth AG |
| 18th Aug 2014 | 7:00 am | RNS | Belixos® launched on Amazon |
| 14th Aug 2014 | 7:00 am | RNS | Change of Trading Currency |
| 11th Aug 2014 | 7:00 am | RNS | Ameluz® first stage approval process Israel |
| 6th Aug 2014 | 7:00 am | RNS | First Ameluz® sales in Central Eastern Europe |
| 27th Jun 2014 | 2:53 pm | RNS | Result of AGM |
| 3rd Jun 2014 | 7:00 am | RNS | AIM Admission - First Day of Dealings |
Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.
To access our Live RNS you must confirm you are a private investor by using the button below.